Articles tagged with Kinase Inhibitors
Researchers aim to understand the role of FAK in promoting key changes in vascular smooth muscle cells that contribute to atherosclerosis. Preliminary evidence suggests that inhibiting FAK may block VSMC transdifferentiation and promote plaque stability.
Neflamapimod, a p38α kinase inhibitor, demonstrates reversible neurodegeneration in animal models and improves clinical endpoints associated with cholinergic neuronal function in patients with dementia with Lewy bodies. The findings support the initiation of a confirmatory Phase 2b clinical trial for neflamapimod.
A study by CNIC scientists has identified a key role for the MKK3/6–p38γ/δ signaling pathway in cardiac hypertrophy. Inhibition of p38α promotes an unexpected activation of the other branch of the pathway, consisting of the proteins MKK3, p38γ, and p38δ. This activation induces another key pathway in cardiac hypertrophy, the mTOR pathway.
A novel preclinical drug has been developed to inhibit the kinase enzyme Cdk5, which is implicated in neuropsychiatric and neurodegenerative conditions. The drug, 25-106, is brain-permeable and shows promise in altering neurobehavior in mice with anxiety-like behavior.
Researchers developed CancerOmicsNet, a graph neural network model that integrates multiple heterogeneous data to predict cancer cell growth rate after drug treatment. The model achieved significantly higher cross-validated accuracy than other approaches on the same data.
Researchers have found that treating prostate cancer cells with novel CDK8 and CDK19 inhibitors reduces their potential to migrate into surrounding structures. This suggests a promising approach to overcome resistance against anti-androgenic therapy, offering new therapeutic options for patients with advanced disease.
Researchers developed a method to identify aggressive early-stage lung cancers and target drugs to tumors likely to respond. They used genomics network models and identified signature genes associated with tumor invasiveness.
Researchers identified water molecules' impact on protein dynamics and drug target residence time, suggesting that a long target residence time can be important for drug efficacy. This understanding enables more rational drug design in the early stages of drug discovery projects.
Researchers found that combining an Aurora Kinase A inhibitor with a KRAS inhibitor or WEE1 inhibitor showed efficacy against lung cancer cells resistant to KRAS inhibition. The study suggests that Aurora Kinase A activation contributes to intrinsic and acquired resistance to sotorasib in KRAS-mutated lung cancer cells.
A new precision medicine test has been developed using blood proteins to identify patients with idiopathic multicentric Castleman disease (iMCD) most likely to respond to siltuximab. The study also reveals Janus kinase (JAK) inhibitors as a promising alternative treatment option for those who do not respond to siltuximab.
Researchers have identified a new potential treatment for neuroblastoma by targeting the ALT mechanism, which is responsible for chemotherapy resistance. The study found that activating ATM kinase at telomeres promotes chemotherapy resistance in ALT neuroblastoma and suggests a cancer-specific approach to treating this disease.
The June edition of SLAS Discovery features the cover article on developing high-throughput biochemical assays to assess small molecule impact on SARS-CoV-2 nonstructural protein 14. The issue also includes nine original research articles, covering topics such as HIV latency reversal, kinase inhibitors, and drug combination screening.
Australian scientists have discovered a new and effective way to treat high-risk blood cancer in children. A combination of ruxolitinib with commonly used anticancer drugs showed enhanced treatment efficacy in two out of three patient-derived xenograft models, achieving long-term suppression of leukaemia growth.
Researchers at the University of Helsinki discovered that HIV's Nef protein activates protein kinases, leading to chronic immune activation and disease progression. The study suggests repurposing kinase inhibitors as a new treatment option for patients whose immunodeficiency is not reversed by current therapies.
A multi-university team identified a family of enzymes called GCK-IV kinases that inhibit robustly neuroprotective while allowing axon regeneration. This finding suggests strong therapeutic possibilities for treating neurodegenerative diseases such as glaucoma and Alzheimer's.
Researchers at Temple University Health System discovered a mechanism behind drug resistance in leukemia cells and found that combining PARP inhibition with TGFBR kinase blockade can overcome resistance. This breakthrough could lead to a new treatment strategy for leukemia patients.
Researchers discovered that combining an ATM inhibitor with a histone deacetylase inhibitor increases apoptosis and decreases p21 expression, allowing for more effective cancer treatment. The study found that the ATM inhibitor nullifies the HDAC inhibitor's ability to induce p21, leading to synergistic effects.
A preclinical study characterized quizartinib's binding affinity and selectivity for FLT3, demonstrating its high affinity and preclinical antitumor activity against midostaurin-resistant AML cells. The study aims to evaluate the role of quizartinib in treating relapsed or refractory AML patients.
Researchers at Harvard Medical School and Dana-Farber Cancer Institute identify key molecules supporting lung cancer cell survival, demonstrating simultaneous inhibition of two signaling pathways. This approach could aid in designing drugs that selectively attack multiple proteins, beneficial for managing certain tumors.
A team of investigators from the University of Pittsburgh has identified compounds that block the reactivation of latent HIV-1 in a human cell line. The research, published in Antimicrobial Agents and Chemotherapy, found 12 kinase inhibitors that irreversibly blocked HIV-1 reactivation with minimal toxicity.
A triple combination regimen including adoptive T cell therapy, a PIM kinase inhibitor, and a PD-1 inhibitor boosts T cell persistence and improves survival in a mouse model of melanoma. This treatment doubles the migration of anti-tumor T cells to the tumor site and quadruples survival compared to ACT alone.
A multidisciplinary research team has provided fundamental new insight into the mechanism of dimethyl fumarate, a medical drug used to treat multiple sclerosis and psoriasis. The results describe an allosteric covalent inhibition of p90 ribosomal S6 kinases, pointing to an effective mechanism of kinase inhibition.
Researchers found a combination treatment combining a CK2 inhibitor with an immune checkpoint inhibitor dramatically increased antitumor activity, eliminating over 60% of tumors in mouse models. The study suggests manipulating the tumor microenvironment may improve clinical outcomes for cancer patients.
Researchers have developed a new treatment that delivers an inflammation inhibitor directly to the kidneys, reversing the course of destructive nephritis. The treatment restores mitochondrial function and reduces cell death, offering hope for patients with chronic kidney disease.
Researchers discovered that FDA-approved kinase inhibitors can curb lung tumor growth in mouse models, offering new therapeutic avenues for a hard-to-treat form of lung cancer. The findings highlight the potential of targeting ERBB receptor tyrosine kinases and EGFR signaling pathways to develop alternative treatment strategies.
Researchers have identified new drug candidates that target multiple protein kinase families to reduce inflammation in COPD. The Narrow Spectrum Kinase Inhibitors (NSKIs) show promising anti-inflammatory effects and may constitute a breakthrough in treating advanced lung disease.
Kinase inhibitors show promise in treating various types of blood and lung cancers by blocking overactive enzymes that control cell growth. Researchers identified new target structures for drugs, including the kinase MELK, which is linked to poor prognosis in lung cancer.
A new study has identified a promising treatment to reduce brain injury in newborns who have suffered from hypoxia-ischemia, a condition that can cause severe complications. The treatment involves combining standard cooling therapy with a selective Src kinase inhibitor to block a regulatory enzyme of apoptosis.
The University of North Carolina at Chapel Hill has developed a potent group of kinase inhibitors, known as the Kinase Chemogenomic Set, which will allow researchers to explore the human kinome in greater depth. The set consists of over 500 compounds and is available for free use by the scientific community.
Researchers found that pre-treatment with an Alk5 inhibitor enhances the delivery of ferumoxytol to tumors, allowing for improved imaging. The study demonstrates potential for Alk5 inhibitors to improve tumor imaging and diagnosis of solid tumors.
Research suggests that salt-inducible kinases may have therapeutic potential for autoimmune diseases. By inhibiting these enzymes, scientists were able to limit the production of inflammatory molecules by certain types of human immune cells, increasing levels of anti-inflammatory IL-10 and reducing proinflammatory cytokines.
A new class of drug, YELIVA™ (ABC294640), has shown promise in slowing the growth of castration-resistant prostate cancer cells by inhibiting the sphingolipid pathway. The study found that treatment with YELIVA™ increased dihydroceramide levels and reduced expression of key oncogenes.
Researchers discovered a molecular switch that balances the activity of two key proteins in the circadian clock, PER2 and CK1. This finding provides insights into familial advanced sleep phase disorder (FASP) and may lead to new treatment strategies using drugs that inhibit these proteins.
A chemist at San Diego State University developed a new technique to improve the selectivity of protein kinase inhibitors, which can lead to fewer side effects. By locking in either the right- or left-handed version of an atropisomeric compound, researchers found more selective inhibition of specific kinases.
Inhibition of Rho-associated kinase (ROCK) and subsequent cofilin dephosphorylation can promote neurite outgrowth in PC12 cells, a key step towards treating neurodegenerative disorders. Additionally, mesenchymal stem cell transplantation has shown promise in repairing and protecting damaged brain tissue after traumatic injury.
A new compound, MLS-2384, has been developed as a potential anti-tumor therapeutic agent targeting JAK and Src kinases. It exhibits dual inhibitory activity against these kinases and blocks downstream signaling into the STAT3 pathway.
Researchers at UCSB have discovered a new potential target in the fight against Alzheimer's and other neurodegenerative diseases by exploring the possibility of inhibiting hyperphosphorylated tau. The study found that small molecular kinase inhibitors can efficiently reduce tau phosphorylation and exert a neuroprotective effect, restor...
Researchers at Scripps Research Institute design a dual inhibitor attacking leucine-rich repeat kinase 2 (LRRK2) and c-jun-N-terminal kinase (JNK) enzymes, two proteins closely linked to Parkinson's disease development. The compound may offer a more effective treatment by eliminating complications of individual inhibitors.
A new drug has shown significant promise in extending survival when used in combination with radiation therapy for brain cancer patients. The experimental drug, KU-60019, blocks the activation of ATM kinase, leading to enhanced destruction of glioma cells.
Researchers at the University of Michigan discovered that paroxetine inhibits GRK2, a protein kinase involved in heart failure, improving myocardial contractility without affecting heart rate. The team hopes to optimize and develop these compounds into therapeutic leads for heart failure treatment.
Researchers at Sanford-Burnham Medical Research Institute have developed a new method to generate induced pluripotent stem cells (iPSCs) by adding kinase inhibitors, which significantly increase cellular reprogramming efficiency. This breakthrough has the potential to accelerate disease research and drug development.
Researchers developed a new class of compounds that block malaria transmission from humans to mosquitoes by inhibiting bumped kinase I. This approach represents a new strategy for controlling malaria spread. The study's preclinical data in mice suggests the inhibitors are safe and well-tolerated.
Researchers have discovered a potential new treatment for fragile X syndrome by targeting phosphoinositide-3 (PI3) kinase inhibitors. These drugs can correct defects in neurons and restore normal protein production at synapses, suggesting improved learning and cognition in individuals with the condition.
Researchers found a way for healthy cells to take charge of cancerous cells by opening up communication channels, stopping them from developing into tumors. The chemicals, known as kinase inhibitors, appear to be relatively non-toxic and can persist even when withdrawn.
Scientists have uncovered the 3D structure of Mps1, a protein that regulates chromosome number during cell division and prevents cancer. The discovery will help design safer and more effective therapies.
The study reveals that three specific inhibitors of necroptosis, a form of necrotic death, target and inhibit RIP1 kinase, a protein that can direct cells into necrosis. This finding presents a novel avenue for drug development to prevent extensive tissue damage in diseases such as heart attacks and strokes.
Scientists discover a new compound, PI-103, that effectively inhibits the spread of brain cancer by targeting two separate steps in the signaling pathway. This dual blockade proves to be safe and effective in slowing down cancer cell proliferation in mice with human glioma cells.
Researchers discovered a novel compound, PI-103, that cooperatively inhibits both p110α subunit of PI3 kinase and downstream molecule mTOR. This dual inhibition shows high effectiveness against human gliomas in mice without toxicity.
Scientists have identified a potential new treatment for structural heart disease by blocking the activity of a protein called CaM kinase. The findings suggest that inhibiting this protein may prevent or reduce symptoms associated with structural heart disease, including electrical instability and mechanical dysfunction.
Researchers identified a new kinase inhibitor that blocks a different path used by cancer, leading to improved treatment outcomes for chronic myelogenous leukemia (CML) and B-cell acute lymphoblastic leukemia (B-ALL). The study found that the inhibitor impaired proliferation of leukemic cells and prolonged survival in mice with B-ALL.
Researchers at The Scripps Research Institute propose a new therapeutic target to prevent tissue damage caused by stroke, complementing current clot-dissolving treatments. Administering a Src kinase inhibitor within hours of stroke may reduce brain injury and potentially prevent long-term neurological damage.
Researchers identified SAANDS compounds as a potential new drug target for inducing apoptosis in abnormal cells. The compounds inhibit cGMP phosphodiesterases, triggering programmed cell death in cancerous and precancerous cells.
Researchers at UT Southwestern Medical Center have discovered how aspirin reduces inflammation by targeting a specific kinase. Aspirin inhibition prevents NF-kB activation and suppresses inflammation, making it an excellent target for developing novel anti-inflammatory agents.
Scientists have discovered how p27 blocks cell growth in virtually all human cancers, providing new hope for developing drugs to halt uncontrolled cell division. The discovery uses X-ray crystallography to reveal the molecular structure of p27 and its interaction with cyclin-CDK complexes.